Alto Neuroscience, Inc. (ANRO) Current Ratio
- Current ratio · latest quarter: Value 14.85×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 14.85× | Current assets / current liabilities. $247.32M ÷ $16.65M ≈ 14.85× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 247.32M USD | Assets, Current |
| Current obligations | 16.65M USD | Liabilities, Current |
| Cash and equivalents | 243.73M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 4.02M USD | Accounts Payable, Current |
| Borrowing debt due within one year | 3.77M USD | Long-term Debt, Current Maturities |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $247.32M | $16.65M | $243.73M | (m) | (m) | (m) | $4.02M | $3.77M | 14.85× |
| 2026-03-31 | $269.13M | $13.12M | $263.76M | (m) | (m) | (m) | $3.37M | $2.14M | 20.52× |
| 2025-12-31 | $177.72M | $11.32M | $176.48M | (m) | (m) | (m) | $1.88M | $585.00K | 15.69× |
| 2025-09-30 | $139.45M | $9.04M | $137.82M | (m) | (m) | (m) | $2.06M | (m) | 15.42× |
| 2025-06-30 | $149.85M | $8.13M | $147.59M | (m) | (m) | (m) | $1.67M | (m) | 18.43× |
| 2025-03-31 | $163.52M | $7.26M | $160.75M | (m) | (m) | (m) | $1.38M | (m) | 22.53× |
| 2024-12-31 | $169.34M | $10.01M | $168.23M | (m) | (m) | (m) | $1.58M | $0.00 | 16.92× |
| 2024-09-30 | $183.53M | $14.02M | $181.70M | (m) | (m) | (m) | $2.25M | $3.53M | 13.09× |
| 2024-06-30 | $195.41M | $9.84M | $193.12M | (m) | (m) | (m) | $1.84M | $2.32M | 19.85× |
| 2024-03-31 | $208.31M | $8.01M | $205.90M | (m) | (m) | (m) | $2.41M | $1.15M | 26.02× |
| 2023-12-31 | $85.39M | $5.61M | $82.55M | (m) | (m) | (m) | $1.07M | (m) | 15.22× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |